1270034-25-7

Basic information

• Product Name: 5-(tert-butoxycarbonylaMino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid
• Synonyms: 5-(tert-butoxycarbonylaMino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid
• CAS NO: 1270034-25-7
• Molecular Formula: C₁₅H₁₄F₂N₂O₄S
• Molecular Weight: 356.3444664
• EINECS: -0
• Mol File: 1270034-25-7.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Density: 1.440±0.06 g/cm3(Predicted)
• PKA: 2.76±0.36(Predicted)
• CAS DataBase Reference: 5-(tert-butoxycarbonylaMino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(tert-butoxycarbonylaMino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid(1270034-25-7)
• EPA Substance Registry System: 5-(tert-butoxycarbonylaMino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid(1270034-25-7)

Safety Data

• Hazardous Substances Data: 1270034-25-7(Hazardous Substances Data)

Usage

Description

5-(tert-butoxycarbonylamino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid is a thiazole derivative with the molecular formula C15H13F2N3O4S. It belongs to the class of carboxylic acids and is also known as a tert-butyloxycarbonylamino-protected thiazole carboxylic acid. This chemical compound is commonly used in organic synthesis, particularly in the production of pharmaceuticals and agrochemicals. Its unique structure and properties make it useful in the development of new compounds with potential biological activity. This chemical may have applications in the fields of medicine, agriculture, and material science.

Uses

Used in Pharmaceutical Industry:
5-(tert-butoxycarbonylamino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid is used as a key intermediate in the synthesis of pharmaceuticals for its potential biological activity. Its unique structure allows for the development of new compounds with therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 5-(tert-butoxycarbonylamino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid is used as a building block in the creation of new agrochemicals, contributing to the development of effective and environmentally friendly products for agriculture.
Used in Material Science:
5-(tert-butoxycarbonylamino)-2-(2,6-difluorophenyl)thiazole-4-carboxylic acid is utilized in material science for the development of novel materials with specific properties, such as improved stability or reactivity, due to its unique chemical structure.

Upstream product

• 1620011-01-9 methyl 5-[(tert-butoxycarbonyl)amino]-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxylate 
• 1620011-00-8 methyl 2-bromo-5-[(tert-butoxycarbonyl)amino]-1,3-thiazole-4-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1187056-41-2 ethyl 5-amino-2-(2,6-difluorophenyl)thiazole-4-carboxylate 
• 1187056-39-8 N-(1-cyano-2-ethylperoxyethyl)-2,6-difluorobenzamide 

Downstream Products

• 1620011-48-4 3-({[5-[(tert-butoxycarbonyl)amino]-2-(2,6-difluorophenyl)-1,3-thiazol-4-yl]carbonyl}amino)-4-{(3S)-3-[(tert-butoxycarbonyl)amino]piperidin-1-yl}-6,7-dihydro-5H-cyclopenta[b]pyridin-7-yl acetate 
• 1620011-86-0 (3S,4S)-5-amino-N-{4-[3,4-trans-3-amino-4-hydroxypiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620015-15-7 C₃₉H₅₄F₂N₆O₆SSi 
• 1620011-89-3 (3R,4R)-5-amino-N-{4-[3,4-trans-3-amino-4-hydroxypiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620011-94-0 C₃₄H₃₈F₂N₆O₇S 
• 1620012-01-2 C₄₀H₅₆F₂N₆O₆SSi 
• 1620011-98-4 5-amino-N-{4-[(3R,4R,5S)-3-amino-4-hydroxy-5-methylpiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620012-04-5 C₃₈H₅₀F₂N₆O₆S₂Si 
• 1620012-02-3 5-amino-N-{7-[(3R,4R)-3-amino-4-hydroxypiperidin-1-yl]thieno[3,2-b]pyridin-6-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620012-08-9 C₃₃H₃₄F₂N₆O₇S₂ 
• 1620011-18-8 5-amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-5-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620011-55-3 5-amino-N-{4-[(3S)-3-aminopiperidin-1-yl]-7-methoxy-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 
• 1620011-57-5 C₃₄H₄₂F₂N₆O₆S 
• 1620015-17-9 (3R,5S)-5-amino-N-{4-[3,4-cis-3-amino-4-hydroxypiperidin-1-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-3-yl}-2-(2,6-difluorophenyl)-1,3-thiazole-4-carboxamide 

Relevant articles and documents

Optimization of Pan-Pim Kinase Activity and Oral Bioavailability Leading to Diaminopyrazole (GDC-0339) for the Treatment of Multiple Myeloma

Pim kinases have been targets of interest for a number of therapeutic areas. Evidence of durable single-agent efficacy in human clinical trials validated Pim kinase inhibition as a promising therapeutic approach for multiple myeloma patients. Here, we report the compound optimization leading to GDC-0339 (16), a potent, orally bioavailable, and well tolerated pan-Pim kinase inhibitor that proved efficacious in RPMI8226 and MM.1S human multiple myeloma xenograft mouse models and has been evaluated as an early development candidate.

THIAZOLECARBOXAMIDES AND PYRIDINECARBOXAMIDE COMPOUNDS USEFUL AS PIM KINASE INHIBITORS

The present disclosure describes thiazole and pyridine carboxamide derivatives, their compositions and methods of use. The compounds inhibit the activity of the Pim kinases and are useful in the treatment of diseases related to the activity of Pim kinases including, e.g., cancer and other diseases.

CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.